Related Experiment Video
Updated: Jun 16, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
Recurrent Severe Hypophosphatemia Following Intravenous Ferric Carboxymaltose Infusion: A Case Report
Louis A Enchill1, Ogheneakpobor E Ubogun1, Shantoi Williams1
1Internal Medicine, Montefiore St. Luke's Cornwall Hospital, Newburgh, USA.
None:
Hypophosphatemia is an increasingly recognized complication of intravenous (IV) iron therapy, particularly with ferric carboxymaltose (FCM). We present a case of recurrent, symptomatic hypophosphatemia requiring hospitalization following IV FCM infusions, highlighting the clinical course, management challenges, and underlying mechanisms. This case highlights the importance of early recognition, risk stratification, and laboratory monitoring in patients receiving IV iron. It also highlights the importance of carefully selecting patients who truly need IV iron per standard guidelines and the appropriate selection of a specific IV iron formulation based on the patient's background characteristics.
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Hemodialysis II: Procedure and Complications
Peritoneal Dialysis III: Nursing Management
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Acute Kidney Injury III: Clinical Manifestations

